Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial

MLA

Lai Xu, et al. “Short-Term Outcomes of Complete Mesocolic Excision versus D2 Dissection in Patients Undergoing Laparoscopic Colectomy for Right Colon Cancer (RELARC): A Randomised, Controlled, Phase 3, Superiority Trial.” The Lancet. Oncology, vol. 22, no. 3, Sept. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....45339db6698ac106bb8c8647318d3e7d&authtype=sso&custid=ns315887.

APA

Lai Xu, Xiangqian Su, Zirui He, Chenghai Zhang, Junyang Lu, Guannan Zhang, Yueming Sun, Xiaohui Du, Pan Chi, Ziqiang Wang, Ming Zhong, Aiwen Wu, Anlong Zhu, Fei Li, Jianmin Xu, Liang Kang, Jian Suo, Haijun Deng, Yingjiang Ye, … Bin Li. (2020). Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial. The Lancet. Oncology, 22(3).

Chicago

Lai Xu, Xiangqian Su, Zirui He, Chenghai Zhang, Junyang Lu, Guannan Zhang, Yueming Sun, et al. 2020. “Short-Term Outcomes of Complete Mesocolic Excision versus D2 Dissection in Patients Undergoing Laparoscopic Colectomy for Right Colon Cancer (RELARC): A Randomised, Controlled, Phase 3, Superiority Trial.” The Lancet. Oncology 22 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....45339db6698ac106bb8c8647318d3e7d&authtype=sso&custid=ns315887.